Skip to main content
    A

    Alector Inc (ALEC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.57
    +0.03 (+1.18%)

    Market Cap: $378.15M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Alector Inc (ALEC) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Alector (ALEC) trades at 7.3x trailing earnings and 1.7x sales. Its P/S of 1.7x is below its 5-year median of 5.1x. Its forward P/E is 8.5x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 14.1% lower over the next year.

    MultipleValue
    P/E (trailing)7.3x
    Forward P/E8.5x
    Price to sales1.7x
    Price to book2.5x
    EV/EBITDA4.4x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S1.7x5.1xN/A
    P/B2.5x3.0xN/A
    Medians of month-end values through Oct 2026: 57 to 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 1.8x in 2024 to 371.9x in 2019.

    Year endPriceP/SP/B
    2025$1.567.5x5.2x
    2024$1.891.8x1.5x
    2023$7.986.9x5.0x
    2022$9.235.7x3.6x
    2021$20.658.1x5.6x
    2020$15.1355.6x4.5x
    2019$17.23371.9x6.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ALEC

    What is ALEC's forward P/E ratio?

    Alector has a forward P/E ratio of 8.5x.

    Is ALEC stock overvalued?

    GNG's valuation label for ALEC is Overvalued.

    What is ALEC's price to sales ratio?

    Alector has a price to sales ratio of 1.7x.